Kiniksa Pharmaceuticals, Ltd.
NASDAQ:KNSA
Overview | Financials
Company Name | Kiniksa Pharmaceuticals, Ltd. |
Symbol | KNSA |
Currency | USD |
Price | 20.02 |
Market Cap | 1,445,475,291 |
Dividend Yield | 0% |
52-week-range | 16.56 - 28.15 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Sanj K. Patel |
Website | https://www.kiniksa.com |
An error occurred while fetching data.
About Kiniksa Pharmaceuticals, Ltd.
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD